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Introduction: To report oncological outcomes of ESRD patients with
histories of urological malignancies who subsequently underwent
kidney transplantation (KT).
Materials andmethods: A chart review of the 1,200 patients who had
KTat the Foundation Puigvert (Barcelona) from1988 to 2018 identified
all cases of urological malignancies treated before kidney transplant-
ation. Baseline characteristics, initial staging, treatment and follow-up
were noted as well as the chronology of the ignition of dialysis,
inscription on the waiting list and kidney transplantation. Endpoints
included cancer recurrence, metastasis, death related to cancer and
overall survival.
Results: 85 urological malignancies in 81 patients were identified: 15
(18%) prostate cancers, 49 (58%) RCC, 19 (22%) urothelial carcinomas
and 2 (2%) testicular cancers. Median age at cancer treatment was 57
years [25–79]. A majority of patients received kidneys from deceased
donors (76%) and had hemodialysis before KT (96%).Median time from
cancer treatment to kidney transplantation was 4.8 years: prostate
cancer 3.7 years, RCC 3.9 years, bladder cancer 8.8 years. Median
overall survival after cancer treatment was 25.3 years and cancer-
specific survival was 95% at 25 years. Themedian time from ignition of
dialysis to kidney transplantation was 22 months in patients with
histories of urological malignancy versus 6 months in the total cohort
of 1,200 renal transplanted over the same period.
Conclusions: Well-selected patients with histories of urological
malignancies benefit greatly from kidney transplantation with
infrequent and late cancer recurrence. We suggest optimizing the
management of patients with low-risk prostate cancers and RCC by
shortening waiting time.
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Introduction: RAKT from living donors (LD) is increasingly performed
in selected centers with experience in robotic surgery and kidney
transplantation (KT). Of note, KT from LD using right-sided graft (RSG)
is challenging due to the brevity of the right renal vein and has been
associatedwith a higher risk of perioperative complications in selected
series. In this scenario, RAKT may facilitate the performance of
vascular anastomoses in case of short renal vessels thanks to the
advantages of the robotic platform. However, the evidence on the
safety and feasibility of RAKT using RSGs is lacking. The aim of this
study is to compare the surgical and early perioperative outcomes after
RAKT from LD using right- vs. left-sided grafts in a large prospective
multicenter cohort (ERUS-RAKT working group).
Materials and methods: After ethical committee approval, data from
patients undergoing RAKT with regional hypothermia from LD using
RSGs at 10 European referral centers between July 2015 and September
2019 were prospectively collected in a dedicated database. Patients
undergoing RAKT using left-sided grafts (LSG) were used as controls.
RAKT was performed following the principles of the Vattikuti-
Medanta technique. Intraoperative outcomes and early (30d) post-
operative complications (classified using the Clavien-Dindo classifi-
cation), as well as functional results, were the main study endpoints.
Results: Overall, 291 RAKTs were performed during the study period.
Of these, 15% were from RSG. The study groups were comparable
regarding all donor-, recipient- and graft-related characteristics.Warm
and cold ischemia times were also comparable between the two study
groups. The median times to complete venous and arterial anasto-
moses, as well as median rewarming time, were significantly higher
during RAKT using RSG (23 vs. 19 min, p = 0.001; 22 vs. 18 min,
p < 0.001 and 55 vs. 50min p = 0.001, respectively), whilemedian time
to complete the ureteral-vesical anastomosis and median estimated
blood loss were comparable between the two groups. There was no
difference between the two study groups regarding both the median
30 d-eGFR and the rate of perioperative surgical complications.
Conversely, RAKT using RSG was associated with lower 7 d-eGFR as
compared to RAKT using LSG (47.2 vs 53.0 ml/min/1.73 m2, p = 0.013);
yet, at multivariable analysis, kidney side was not significantly
associated with worse 7d-eGFR.
Conclusions: Our preliminary experience outlines that RAKT using
RSGs is technically feasible and may achieve noninferior early
perioperative and functional outcomes as compared RAKT using
LSGs. Larger studies with longer follow-up are needed to confirm our
findings.
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Introduction: The progressive increase of patients with ESRD has
caused a worldwide shortage of organs for kidney transplantation
(KT). As such, the use of kidneys from both “extended criteria” donors
after brain dead (eDBD) and uncontrolled donors after circulatory
death (uDCD) has been warranted. In this study we report our 3-year
experiencewith KT using grafts from eDBD vs uDCD, focusing on graft
survival, perioperative and functional outcomes.
Materials andmethods:We queried our prospectivelymaintained KT
database to select patients undergoing KT from uDCD and eDBD from
January 2017 to December 2019 at our Centre. Static cold storage was
employed for grafts from e-DBDs, while hypothermic machine
perfusion for those from uDCDs (LifePort kidney transporter, Organ
Recovery Systems). The main study endpoints were postoperative
complications, delayed graft function (DGF), and eGFR at a short- and
mid-term follow-up.
Results: Overall, 140 KTs from deceased donors were performed
during the study period. Of these, 31were from uDCD (22.1%) while 46
(32.9%) from eDBDs (overall, 55% of all deceased donors). Compared to
uDCDs, the eDBDs were older and had a significantly higher
preoperative eGFR; recipients from uDCDs were younger and had a
lower median Charlson Comorbidity Index (2 vs 3). No differences
between the two groupswere found regarding the cold ischemia time,
surgical approach, intraoperative complications, and times for vascular
and ureteral anastomoses. The proportion of patients experiencing
graft nephrectomy was higher in the uDCD group (9.6% vs 2.2%,
p = 0.1], as well as major (Clavien-Dindo grade 3–5) postoperative
surgical complications [25.8% vs 21.7, p = 0,6]. Patients undergoing KT
from uDCDs had a significantly longer median length of
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